Dexcom
DexCom, Inc. (Nasdaq: DXCM) is a medical device company focused on continuous glucose monitoring (CGM) systems for diabetes management and metabolic health. Its products provide ongoing glucose readings, trends and alerts to patients, caregivers and clinicians, and connect with mobile devices, cloud-based reporting… From the company’s description.
In fiscal 2025, Dexcom reported revenue of $4.66B, up 15.6% from fiscal 2024, and net income of $836.30M. Its operating margin was 19.6%, and operations generated $1.44B in cash. Over the twelve months to Jun 30, 2026, revenue was $4.97B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Dexcom does
In the company’s own words
DexCom, Inc. (Nasdaq: DXCM) is a medical device company focused on continuous glucose monitoring (CGM) systems for diabetes management and metabolic health. Its products provide ongoing glucose readings, trends and alerts to patients, caregivers and clinicians, and connect with mobile devices, cloud-based reporting tools and compatible insulin delivery systems. Its offerings include the Dexcom G7 and G7 15 Day CGM systems, Dexcom ONE+, and Stelo, an over-the-counter glucose biosensor for adults with prediabetes and Type 2 diabetes who do not use insulin. Dexcom also provides remote monitoring through Dexcom Share and Follow and collaborates with insulin-delivery and digital-health partners. The company sells to customers through direct sales and distribution arrangements, serving people with diabetes and those seeking to manage metabolic health, as well as healthcare professionals and other care providers. Dexcom reports one operating segment. Revenue was $4.6 billion in fiscal 2025. Its major brands include Dexcom, Dexcom Clarity and Stelo. Its website is www.dexcom.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- December
- CIK
- 1093557
- SIC
- 3841
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Dexcom — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Dexcom’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Dexcom’s bonds, as funds hold them
Funds report holding 1 issues of Dexcom’s debt, $139.82M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 0.38%, maturing 2028 to 2028.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Dexcom and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Dexcom's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Dexcom's last four quarterly filings that the numbers alone won't show?”